相关实验视频

Updated: Jul 28, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

最近的洞察力Osimertinib对EGFR阳性非小细胞肺癌的类似物

Jatin Chhabra¹, Priyanka Kashyap¹, Rakesh Pahwa¹

¹Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, 136119, India.

Current topics in medicinal chemistry

|June 5, 2023

概括

奥西默提尼布是治疗非小细胞肺癌 (NSCLC) 的关键药物,但耐药性发展. 新的奥西默提尼布衍生物在治疗NSCLC时有望提高疗效和安全性.

科学领域:

在瘤学瘤学.
药用化学医学化学
药理学药理学是指药理学的学科.

背景情况:

肺癌是全球主要的死亡原因,突变使治疗复杂化.
表皮生长因子受体 (EGFR) 突变对于肺癌的发展至关重要.
奥西默提尼布是一种第三代EGFR抑制剂,治疗非小细胞肺癌 (NSCLC),但往往导致耐药性.

研究的目的:

审查奥西默蒂尼布及其衍生物在NSCLC治疗中的最新进展.
突出具有增强抗瘤潜力和安全性的新类型.
总结针对EGFR的奥西默提尼布类型的合成策略.

主要方法:

从PubMed,ScienceDirect和谷歌学者搜索过去七年的文献.
关于奥西默提尼布衍生物及其在NSCLC中的疗效的研究综述.
对新型奥西默提尼布类似物合成方案的分析.

主要成果:

最近的进展集中在有改善抗瘤活性的奥西默提尼布类型上.
新衍生药物表明,在NSCLC治疗中,其安全性可能有所提高.
在全球范围内,已经报告了这些类似物的各种合成途径.

结论:

该审查涵盖了奥西默提尼布的机制性见解,分析方面,药物相互作用,药理动力学和耐药性概况.
了解这些因素对于开发更有效的NSCLC疗法至关重要.
对奥西默提尼布衍生物的进一步研究可能会克服治疗耐药性并改善患者的治疗结果.

关键词:

化疗化疗是一种化学疗法.欧洲农业基金会 (EGFR) 是一个基金.流氧葡萄糖是流氧葡萄糖的一种.发生突变的EGFR.非小细胞肺癌是非小细胞肺癌.奥西默蒂尼布衍生品奥西默蒂尼布衍生品

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...